Geron surges after winning first US FDA approval for blood disorder drug

Shares of Geron (GERN.O) surged more than 30% on Friday, a day after the company gained its first approval from the U.S. Food and Drug Administration for its blood disorder drug.

The health regulator's nod allows the injectable drug, branded as Rytelo, to be used for treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS), a group of blood cancers.